Nowadays, the most frequently used biomarkers used to guide diagnostic and treatment decisions for breast cancer patients are hormone receptors (estrogen, progesterone, and HER2 receptor) and the proliferation marker Ki-67 assessed by immunohistochemical analysis. This evidence concerns the gene NR4A1 and breast cancer.